

News Release

Bayer Schering Pharma Appoints New Medical Director

Newbury, Berkshire, 20th July, 2009 – Dr. Luis Felipe Graterol has taken on the role of Medical Director at Bayer Schering Pharma (BSP) UK. He replaces Dr. Peter Longthorne, who has decided to retire after working with Schering Healthcare and then BSP for nearly 30 years.

Dr. Graterol will now head a medical department of just over 100 people at BSP's head office in Newbury, Berkshire. He joined BSP in 1995 and has held a number of international medical roles during his time with the company. Dr. Graterol first started working on clinical trials in Bayer S.A. Venezuela (South America) and was then promoted to Associate Medical Director, before moving to Bayer's headquarters in Germany, and later to Canada, where he specialised in drug safety. In August 2003, he moved to the UK and became Head of Drug Surveillance where he has remained ever since.

"We work in a challenging environment, therefore it is essential to have a strong team around you that is able to operate effectively within clearly defined parameters, yet still manages to challenge the status quo," comments Dr. Graterol. "I am in a fortunate position to be working with a group of very capable and motivated individuals and to have the opportunity to build on what is already an accomplished team."

BSP employs 388 people in the UK and had total annual sales of just over £200 million in 2008. The company focuses on four main therapeutic areas, these include;

General Medicine - providing treatments to prevent blood clots in patients undergoing elective hip and knee replacement surgery, testosterone deficiency syndrome, erectile dysfunction and pulmonary hypertension.

Specialty Medicine – focusing on the areas of **Oncology**; which provides treatments for renal cell carcinoma, hepatocellular carcinoma, B-cell non-Hodgkin's lymphoma and bone diseases associated with cancer, and **Haematology & Neurology**; consisting of treatments for haemophilia A and multiple sclerosis.

Women's Healthcare – as the global market leader in hormonal contraception, this division provides a range of oral and non-oral contraceptives, as well as therapies for gynaecological and menopausal complaints.

Diagnostic Imaging – providing contrast media for classic X-ray procedures, computed tomography and ultrasound. BSP is the global market leader in the field of contrast media for magnetic resonance imaging (MRI) and is playing a pioneering role in magnetic resonance angiography (MRA).

- Ends -

Contact for further information:

Sophia Cadman

Communications & PR Manager, Bayer Schering Pharma

Tel: +44 (0)1635 563235

Email: sophia.cadman@bayerhealthcare.com

About Bayer Schering Pharma

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company, which had total global sales of €10.7 billion in 2008. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialised markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of patients' lives.

Further information can be found at www.bayerscheringpharma.co.uk

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.